Gut microbiota modification by diosgenin mediates antiepileptic effects in a mouse model of epilepsy
Journal of Neurochemistry · 2024
DOI: 10.1111/jnc.16033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurochemistry, 2024. Verfasst von Xinyu Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology and Neurobiology, Xuzhou Key Laboratory of Neurobiology, Xuzhou Medical University, Xuzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Diosgenin, Gastrointestinal Microbiome, Epilepsy, Disease Models, Animal. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Graduate Research and Innovation Projects of Jiangsu Province, Natural Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
Diosgenin, a natural steroid saponin, holds promise as a multitarget therapeutic for various diseases, including neurodegenerative conditions. Its efficacy in slowing Alzheimer's disease, Parkinson's disease, multiple sclerosis, and stroke progression has been demonstrated. However, the role of diosgenin in anti‐epilepsy and its potential connection to the modulation of the intestinal microbiota remain poorly understood. In this study, exogenous diosgenin significantly mitigated pentylenetetrazole (PTZ)‐induced seizures, learning and memory deficits, and hippocampal neuronal injury. 16S ribosomal RNA (16S rRNA) sequencing revealed a reversal in the decrease of Bacteroides and Parabacteroides genera in the PTZ‐induced mouse epileptic model following diosgenin treatment. Fecal microbiota transplantation (FMT) experiments illustrated the involvement of diosgenin in modulating gut microbiota and providing neuroprotection against epilepsy. Our results further indicated the repression of enteric glial cells (EGCs) activation and the TLR4‐MyD88 pathway, coupled with reduced production of inflammatory cytokines in the colonic lumen, and improved intestinal barrier function in epilepsy mice treated with diosgenin or FMT. This study suggests that diosgenin plays a role in modifying gut microbiota, contributing to the alleviation of intestinal inflammation and neuroinflammation, ultimately inhibiting epilepsy progression in a PTZ‐induced mouse model. Diosgenin emerges as a potential therapeutic option for managing epilepsy and its associated comorbidities. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cell Biology and Neurobiology, Xuzhou Key Laboratory of Neurobiology, Xuzhou Medical University, Xuzhou, Jiangsu, China.
- Department of Neurology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
- Rehabilitation Therapy, Fenyang College of Shanxi Medical University, Fenyang, Shanxi, China.
ORCID-Profile: Ruiqin Yao
Förderung
- Graduate Research and Innovation Projects of Jiangsu Province
- Natural Science Foundation of Jiangsu Province
Zitieren
APA
Li, X., Li, J., Ji, J., Li, S., Yao, X., Fan, H., & Yao, R. (2024). Gut microbiota modification by diosgenin mediates antiepileptic effects in a mouse model of epilepsy. Journal of Neurochemistry. https://doi.org/10.1111/jnc.16033
Vancouver
Li X, Li J, Ji J, Li S, Yao X, Fan H, et al. Gut microbiota modification by diosgenin mediates antiepileptic effects in a mouse model of epilepsy. Journal of Neurochemistry. 2024. doi:10.1111/jnc.16033
BibTeX
@article{Li2024,
author = {Li, Xinyu and Li, Jing and Ji, Jia and Li, Saisai and Yao, Xiaoyu and Fan, Hongbin and Yao, Ruiqin},
title = {Gut microbiota modification by diosgenin mediates antiepileptic effects in a mouse model of epilepsy},
journal = {Journal of Neurochemistry},
year = {2024},
doi = {10.1111/jnc.16033}
}
EUVIMED